Pfizer plans to sell its covid vaccine at a 10,000% markup in 2023

Pfizer will charge as much as $130 for Comirnaty, which costs an estimated $1.18 per dose to produce

Image credit:

By Annalisa Merelli

For over two years now, the US government has purchased all of the covid vaccines administered in the country, in what has become the largest public vaccination campaign in American history.

Those purchases have included more than 500 million doses from Pfizer. The first 100 million cost around $20 a dose, thanks to an earlier agreement in which the US government invested $1.95 billion in vaccine production. The remaining doses were bought for around $30 each.

But once the US government supplies run out (likely in the first quarter of 2023) and covid vaccines and therapeutics are moved onto commercial health platforms, Pfizer is able to hike up the price of its shots.

The company announced on Oct. 20 that it intends to sell the covid vaccine, marketed under the brand name Comirnaty, for $110 to $130 per dose. This is about four times the current selling price—and 100 times the estimated cost of manufacturing the vaccine.

It costs an estimated $1.18 to produce a vial of vaccine